乳腺癌患者体内他莫昔芬的群体药代动力学研究

doi:10.12092/j.issn.1009-2501.2019.04.009

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (4): 418-423.doi: 10.12092/j.issn.1009-2501.2019.04.009

乳腺癌患者体内他莫昔芬的群体药代动力学研究

吴敏¹，过怿赟²，谢海棠²

¹芜湖市第二人民医院药耗供应部，芜湖 241001，安徽；²皖南医学院弋矶山医院临床药学部，芜湖 241001，安徽

收稿日期:2018-11-26 修回日期:2018-12-13 出版日期:2019-04-26 发布日期:2019-05-01
通讯作者: 谢海棠，女，博士，研究员，教授，硕士生导师，研究方向为定量药理学与临床药代动力学。 Tel：13855389779 E-mail：xiehaitang@sina.com
作者简介:吴敏，女，本科，主管药师，主要从事医院药学方向研究。 Tel：18055316014 E-mail：wu_min911@hotmail.com
基金资助:
国家自然科学基金资助项目（81173134）；皖南医学院中青年科研基金资助项目（WK2015F11）

Population pharmacokinetics of tamoxifen in patients with breast cancer

WU Min ¹, GUO Yiyun ², XIE Haitang ²

¹Department of Drug and Consumable Supply, the Second People's Hospital of Wuhu, Wuhu 241001, Anhui, China;² Department of Clinical Pharmacy, Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China

Received:2018-11-26 Revised:2018-12-13 Online:2019-04-26 Published:2019-05-01

摘要/Abstract

摘要：

目的:考察他莫昔芬（TAM）在乳腺癌患者体内的药物代谢动力学特征，以及可能的影响因素。方法:采集规律服用TAM的乳腺癌患者的血液样本，使用HPLC-MS/MS测定TAM及其代谢产物Endoxifen的血药浓度，以非线性混合效应模型法（NONMEM）进行分析，得到群体药代动力学参数，与文献中TAM药代动力学参数进行比较，并用Bootstrap对最终模型进行验证。结果:共29例患者参加该研究，平均年龄（46.9±6.4）岁，体质量指数（BMI）为（23.70±2.87） kg/cm2。最终模型的药代动力学参数估计值分别为，Ka为0.830 h-1；CLTAM为6.61 L/h；CLMET为0.707 L/h；VTAM为753 L；VEND为400 L；CLEND为5.10 L/h；Q为61.8 L。协变量筛选，在向前包容过程中显示有机阴离子转运多肽OATP1B1*521的基因多态性和绝经时间对代谢常数CLTAM有影响（P<0.05），但向后剔除过程未发现有显著性影响的协变量（P<0.001）。Bootstrap结果显示最终模型稳健率达96.8%。结论:本研究成功构建了TAM在乳腺癌患者体内的群体药代动力学模型，并从定量的角度为TAM临床个体化用药提供参考信息。

关键词: 他莫昔芬, 乳腺癌, 群体药代动力学, OATP1B1

Abstract:

AIM:To investigate the population pharmacokinetic characteristics of tamoxifen (TAM) in breast cancer patients and factors that might impact its clearance. METHODS: Blood samples of breast cancer patients who regularly took TAM were collected and the blood concentration of TAM and its metabolite Endoxifen was determined by HPLC-MS/MS and analyzed with nonlinear mixed-effect model (NONMEM). The population pharmacokinetics parameters were compared with those of volunteers in literatures. After that, 1 000 bootstraps were performed to validate the final model. RESULTS:A total of 29 patients took TAM. The mean age and BMI was (46.9±6.4) years and (23.70±2.87) kg/cm2, respectively. Typical population estimates of Ka, CLTAM, CLMET, VTAM, VEND, CLEND, Q were 0.830 h-1, 6.61 L/h, 0.707 L/h, 753 L, 400 L, 5.10 L/h, 61.8 L, respectively. Covariable screening showed OATP1B1*521 gene polymorphism and menopause time had an effect on metabolic constant CLTAM in the process of forward inclusion (P<0.05), but no significant covariable (P<0.001) was found in the process of backward elimination. The model validation of bootstraps results showed the success rate was 96.8%.CONCLUSION: The population pharmacokinetics model of TAM and END is established successfully. And it can provide some information for TAM clinical individualized medication from the perspective of pharmacometrics.

Key words: tamoxifen, breast cancer, population pharmacokinetics, OATP1B1

中图分类号:

吴敏，过怿赟，谢海棠. 乳腺癌患者体内他莫昔芬的群体药代动力学研究[J]. 中国临床药理学与治疗学, 2019, 24(4): 418-423.

WU Min, GUO Yiyun, XIE Haitang. Population pharmacokinetics of tamoxifen in patients with breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 418-423.

参考文献

［1］Cuzick J, Baum M. Tamoxifen and contralateral breast cancer［J］. Lancet, 1985, 2(8449): 282.
［2］Jordan VC.Tamoxifen: a most unlikely pioneering medicine［J］.Nat Rev Drug Discov,2003,2(3):205-213.
［3］Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study ［J］. J Natl Cancer Inst, 2005, 97(22): 1652-1662.
［4］International Breast Cancer Study Group, Colleoni M, Gelber S, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93［J］. J Clin Oncol, 2006, 24(9): 1332-1341.
［5］Early Breast Cancer Trialists' Collaborative Group, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials ［J］. Lancet, 2011, 378(9793): 771-784.
［6］Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials ［J］. Lancet, 2005, 365(9472): 1687-1717.
［7］Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women［J］. N Engl J Med, 1988, 319(26): 1681-1692.
［8］Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer ［J］. Cochrane Database Syst Rev, 2001(1): CD000486.
［9］芮建中, 张震, 李金恒. 群体药代动力学/群体药效动力学原理及研究方法［J］. 医学研究生学报, 2005, 18(3): 246-249.
［10］Sheiner LB. Learning versus confirming in clinical drug development ［J］. Clin Pharmacol Ther, 1997, 61(3): 275-291.
［11］张弨, 赵荣生, 翟所迪, 等. 群体药代动力学概述［J］. 中国临床药理学杂志, 2013, 29(8): 563-565.
［12］ter Heine R, Binkhorst L, de Graan AJ, et al. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen［J］. Br J Clin Pharmacol, 2014, 78(3): 572-586.
［13］Ahmad A, Shahabuddin S, Sheikh S, et al. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects［J］. Clin Pharmacol Ther, 2010, 88(6): 814-817.
［14］陈冰, 杨婉花, 张伟霞, 等. 中国成年患者万古霉素群体药动学研究［J］. 药学与临床研究, 2013, 21(6): 605-609.
［15］Boeckmann A, Sheiner L, Beal S. NONMEM Users Guide ［M］. Part V: 102-103.
［16］凌静, 钱李轩, 丁俊杰, 等. 谷浓度采样设计和算法对群体和个体药动学参数估算的影响［J］. 药学学报, 2014, 49(5): 686-694.
［17］王亚萍, 牛小麟. 基因多态性的研究方法及其临床应用［J］. 临床医学, 2003, 23(9): 49-50.
［18］Pu Z, Zhang X, Chen Q, et al. Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells［J］. Oncol Rep, 2015, 33(5): 2420-2428.
［19］Zhang X, Pu Z, Ge J, et al. Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy ［J］. Med Sci Monit, 2015, 21: 563-569.
［20］Gao CM, Pu Z, He C, et al. Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen ［J］. Oncol Rep, 2017, 38(2): 1124-1132.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	李梦雪, 何杰, 余霞霞, 胡琳璘, 邵华. 利妥昔单抗群体药代动力学研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 468-474.
[9]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[10]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[11]	徐涛, 朱素燕, 邱相君, 徐萍. 肾功能不全患者人群中替考拉宁群体药代动力学模型的建立与验证[J]. 中国临床药理学与治疗学, 2022, 27(9): 977-983.
[12]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[13]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[14]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.
[15]	林良沫, 符祥俊, 钟莉莉, 王和芳, 吴琼诗, 肖坚. 中性粒细胞缺乏患者万古霉素群体药代动力学模型的建立[J]. 中国临床药理学与治疗学, 2021, 26(9): 1014-1022.

乳腺癌患者体内他莫昔芬的群体药代动力学研究

Population pharmacokinetics of tamoxifen in patients with breast cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价